Trial Profile
Longterm Efficacy and Safety of NVP-Based HAART in HIV-1 Positive Patients in the Daily Clinical Practice.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Nevirapine (Primary) ; Antiretrovirals
- Indications HIV-1 infections
- Focus Adverse reactions
- Sponsors Boehringer Ingelheim
- 21 Sep 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 23 Aug 2011 Planned end date changed from Jul 2011 to Sep 2011 as reported by ClinicalTrials.gov.
- 01 Jun 2011 Planned End Date changed from 1 Jun 2011 to 1 Jul 2011 as reported by ClinicalTrials.gov.